GlassScriptPhysician profile
Richard B Ray
NPI 1306147947
$1,971.59
in general payments reported to CMS, 2019-2025
14 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $820 · 2022: $590 · 2023: $207 · 2024: $77.19 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.65 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $340.22 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Alkermes, INC. | $321.13 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $312.02 | 2021-2022 | |
| Lundbeck LLC | $217.28 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.40 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $180.98 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $111.56 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.98 | 2021-2022 | |
| Indivior INC. | $65.47 | 2022-2023 | Perseris |
| Neurocrine Biosciences, INC. | $35.06 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $33.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Bausch Health US, LLC | $13.84 | 2022 | |
| Adlon Therapeutics L.P. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.